Granza Bio
Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunit
Y Combinator
yc-company-directory #5454Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunit
sourceGranza Bio is classified as Healthcare from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.
Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.
Companies similar to Granza Bio
A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.
Tradewind BioScience
match 89Our lead candidate is a multifaceted attack antibody for ovarian cancer. Our approach enables targeting primary cancer cells directly, alongside enabling the immune system's natural anti-cancer function, all with one therapeutic antibody.
shared product terms: therapeutic, immune, system, attack; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator
Asher Bio
match 81Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmu
shared product terms: bio, develop, cancer, disease; shared affiliation: Y Combinator
Trestle Biotherapeutics
match 57We are developing an implantable therapeutic tissue that will be surgically delivered to patients suffering from end stage renal disease. Upon implantation, this tissue will supplement the patient's renal function, eliminating their dependency on dialysis and improving their disease status. This has the potential to not only get these patients off dialysis - a significant impact for them and their families - but to greatly extend the time required before kidney transplantation is essential.
shared product terms: develop, therapeutic, deliver, function; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator
Shield Bio
match 57Shield Bio is a precision medicine company with a proprietary platform that enables reliable nanopore sequencing in under a minute, in a clinical setting. It is focused on bringing 3rd generation or "nanopore" sequencing into clinical use to deliver on the promise of precision medicine. Shield is initially using the technology to improve the treatment of infectious disease and address the unmet clinical need of sepsis, which kills 300,000 people a year in the US alone.
shared product terms: bio, deliver, kill, enable; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator
Eris Biotech
match 49We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma.
shared product terms: develop, cancer, therapeutic, immune; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator
Engage Bio
match 33Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.
shared product terms: bio, develop, clas, potent; shared affiliation: Y Combinator